Authorized purpose: IRISeg receives DICOM-compliant contrast-enhanced CT images, provides manual and machine-learning-enabled image-analysis and segmentation tools, and creates an output file for a three-dimensional model used in preoperative planning and intraoperative display. The kidney CT auto-segmentation tool is indicated for adult patients with contrast-enhanced axial kidney CT images with slice thickness of 3 mm or less.
Clinical role
Medical-image processing, segmentation, enhancement, measurement, quantification, visualization, or reporting support under professional review.
Images and patients
CT/CTA · Kidneys
Key limitation
Keep in mind: The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: IRISeg receives DICOM-compliant contrast-enhanced CT images, provides manual and machine-learning-enabled image-analysis and segmentation tools, and creates an output file for a three-dimensional model used in preoperative planning and intraoperative display. The kidney CT auto-segmentation tool is indicated for adult patients with contrast-enhanced axial kidney CT images with slice thickness of 3 mm or less.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Kidneys Input: Supported medical images, DICOM metadata, patient and protocol information, and release-specific user inputs.
Who uses it?Intended users: Qualified healthcare professionals trained for the exact represented anatomy, modality, and workflow.
What does the software produce?Output: Images, segmentations, measurements, models, calculations, overlays, or reports that require professional review.
What is its most important limitation?Key limitation: The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.
Clinical takeaway. Clinical role: IRISeg receives DICOM-compliant contrast-enhanced CT images, provides manual and machine-learning-enabled image-analysis and segmentation tools, and creates an output file for a three-dimensional model used in preoperative planning and intraoperative display. The kidney CT auto-segmentation tool is indicated for adult patients with contrast-enhanced axial kidney CT images with slice thickness of 3 mm or less.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation, cybersecurity testing, design validation, and bench testing of the kidney CT auto-segmentation algorithm on 81 kidney CT scans, with training/testing independence enforced by scanning institution, against consensus segmentations by three U.S Board Certified Radiologists. 95% two-sided confidence intervals: artery DSC [0.87, 0.90], parenchyma DSC [0.95, 0.97], vein DSC [0.87, 0.89], collecting system MDA [1.3, 1.9]. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
IRISeg receives DICOM-compliant contrast-enhanced CT images, provides manual and machine-learning-enabled image-analysis and segmentation tools, and creates an output file for a three-dimensional model used in preoperative planning and intraoperative display. The kidney CT auto-segmentation tool is indicated for adult patients with contrast-enhanced axial kidney CT images with slice thickness of 3 mm or less.
The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.
The exact FDA document reports software verification and validation, cybersecurity testing, design validation, and bench testing of the kidney CT auto-segmentation algorithm on 81 kidney CT scans, with training/testing independence enforced by scanning institution, against consensus segmentations by three U.S Board Certified Radiologists. 95% two-sided confidence intervals: artery DSC [0.87, 0.90], parenchyma DSC [0.95, 0.97], vein DSC [0.87, 0.89], collecting system MDA [1.3, 1.9]. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The performance testing included software verification, machine-learning algorithm performance testing, cybersecurity testing, and design validation testing." … "A total of 81 kidney CT scans were used to evaluate the algorithm.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification and validation, cybersecurity testing, design validation, and bench testing of the kidney CT auto-segmentation algorithm on 81 kidney CT scans, with training/testing independence enforced by scanning institution, against consensus segmentations by three U.S Board Certified Radiologists. 95% two-sided confidence intervals: artery DSC [0.87, 0.90], parenchyma DSC [0.95, 0.97], vein DSC [0.87, 0.89], collecting system MDA [1.3, 1.9]. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "The performance testing included software verification, machine-learning algorithm performance testing, cybersecurity testing, and design validation testing." … "A total of 81 kidney CT scans were used to evaluate the algorithm.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K242461 FDA decision evidence for IRISeg
DesignFDA 510(k) substantial-equivalence review of the exact submission, device description, indications, and verification or validation documentation.
PopulationKidneys
Scopeexact submission
Tested versionIRISeg Version 3.1
IndependenceSponsor or vendor study
K242461
The FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K242461 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, surgical, or diagnostic service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported medical images, DICOM metadata, patient and protocol information, and release-specific user inputs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes IRISeg opening and loading DICOM CT imaging files and NIfTI label map files from an accessible storage location, and generating an output file that can be used to render virtual segmented kidney 3D models. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "IRISeg can open and load CT imaging files in DICOM (Digital Imaging and Communications in Medicine) format, and label map files (2D segmented labels) in NIfTI (Neuroimaging Informatics Technology Initiative) format from an accessible storage location." … "Following the use of IRISeg to segment kidney CT imaging files, the software can be used to generate an output file that can be used to render virtual segmented kidney 3D models.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes IRISeg as a standalone software application whose listed host hardware compatibility is general-purpose computer hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Host Hardware General-purpose computer General-purpose computer Compatibility hardware hardware" … "IRISeg Version 3.1 (“IRISeg”) is a standalone software application created by Intuitive Surgical for segmentation of contrast-enhanced kidney CT images". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Images, segmentations, measurements, models, calculations, overlays, or reports that require professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Images, segmentations, measurements, models, calculations, overlays, or reports that require professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes IRISeg as a standalone software application whose listed host hardware compatibility is general-purpose computer hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Host Hardware General-purpose computer General-purpose computer Compatibility hardware hardware" … "IRISeg Version 3.1 (“IRISeg”) is a standalone software application created by Intuitive Surgical for segmentation of contrast-enhanced kidney CT images". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes IRISeg opening and loading DICOM CT imaging files and NIfTI label map files from an accessible storage location, and generating an output file that can be used to render virtual segmented kidney 3D models. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "IRISeg can open and load CT imaging files in DICOM (Digital Imaging and Communications in Medicine) format, and label map files (2D segmented labels) in NIfTI (Neuroimaging Informatics Technology Initiative) format from an accessible storage location." … "Following the use of IRISeg to segment kidney CT imaging files, the software can be used to generate an output file that can be used to render virtual segmented kidney 3D models.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Intuitive's product security program page describes a coordinated vulnerability disclosure program scoped to its medical devices, supporting software, web services, and mobile applications (reporting to product.security@intusurg.com with PGP), published security advisories with product impact assessments, and a post-market cybersecurity vulnerability monitoring program covering products including da Vinci, Ion, and digital services.
Vendor-wide
Checked 2026-10-27
Vendor statement. Applicant name variants ('Intuitive Surgical Inc.', 'Intuitive Surgical, Inc.') are the identical distinctive name. Exact-release scope is not established.
Only qualified healthcare professionals trained for the exact represented anatomy, modality, and workflow should operate or interpret this product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.
Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K242461 before acceptance. Later family features are not evidence for this exact submission.
The exact FDA material does not establish a complete interoperability contract. Establish and test supported input, output, identity, routing, archive, and downtime behavior locally.
The exact FDA material does not establish hosting, deployment topology, availability, upgrade path, or service responsibility. Obtain site-specific evidence before procurement.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs. No exact-product price was found.
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
33Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or approved configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.
Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.